DE69621813T2 - IRON-DEXTRAN FORMULATIONS - Google Patents

IRON-DEXTRAN FORMULATIONS

Info

Publication number
DE69621813T2
DE69621813T2 DE69621813T DE69621813T DE69621813T2 DE 69621813 T2 DE69621813 T2 DE 69621813T2 DE 69621813 T DE69621813 T DE 69621813T DE 69621813 T DE69621813 T DE 69621813T DE 69621813 T2 DE69621813 T2 DE 69621813T2
Authority
DE
Germany
Prior art keywords
iron
dextran formulations
dextran
formulations
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69621813T
Other languages
German (de)
Other versions
DE69621813D1 (en
Inventor
P Lawrence
A Lange
Mary Jane Helenek
Chin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vifor International AG
Original Assignee
Luitpold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luitpold Pharmaceuticals Inc filed Critical Luitpold Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69621813D1 publication Critical patent/DE69621813D1/en
Publication of DE69621813T2 publication Critical patent/DE69621813T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Ferric oxyhydroxide-dextran compositions for treating iron deficiency having ellipsoidal particles with a preferred molecular weight range of about 250,000 to 300,000 daltons.
DE69621813T 1995-09-29 1996-08-29 IRON-DEXTRAN FORMULATIONS Expired - Lifetime DE69621813T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/536,984 US5624668A (en) 1995-09-29 1995-09-29 Iron dextran formulations
PCT/US1996/014153 WO1997011711A1 (en) 1995-09-29 1996-08-29 Iron dextran formulations

Publications (2)

Publication Number Publication Date
DE69621813D1 DE69621813D1 (en) 2002-07-18
DE69621813T2 true DE69621813T2 (en) 2003-01-23

Family

ID=24140716

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69621813T Expired - Lifetime DE69621813T2 (en) 1995-09-29 1996-08-29 IRON-DEXTRAN FORMULATIONS

Country Status (11)

Country Link
US (1) US5624668A (en)
EP (1) EP0855913B1 (en)
JP (1) JP3471363B2 (en)
AT (1) ATE218875T1 (en)
AU (1) AU702691B2 (en)
CA (1) CA2184551C (en)
DE (1) DE69621813T2 (en)
DK (1) DK0855913T3 (en)
ES (1) ES2179207T3 (en)
PT (1) PT855913E (en)
WO (1) WO1997011711A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306384B1 (en) * 1996-10-01 2001-10-23 E-L Management Corp. Skin battery cosmetic composition
DK172860B1 (en) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Iron dextran compound for use as a component of a therapeutic agent for the prevention or treatment of iron man
US7670491B2 (en) * 1998-10-20 2010-03-02 Advanced Renal Technologies Buffered compositions for dialysis
US6610206B1 (en) 1998-10-20 2003-08-26 Advanced Renal Technologies Buffered compositions for dialysis
DK173138B1 (en) 1998-11-20 2000-02-07 Pharmacosmos Holding As Process for Preparing an Iron Dextran Compound, Iron Dextran Compound Prepared by the Process, Pharmaceutical
PT1218039E (en) * 1999-09-22 2009-05-25 Advanced Renal Technologies Use of high citrate dialysate
US6929954B2 (en) * 2000-11-02 2005-08-16 Chromaceutical Advanced Technologies, Inc. Method for producing purified hematinic iron-saccharidic complex and product produced
CA2426799A1 (en) * 2000-11-02 2002-07-25 Chromaceutical Advanced Technologies, Inc. Method for producing purified hematinic iron-saccharidic complex and product produced
EP1719495A3 (en) * 2000-11-02 2007-05-02 Chromaceutical Advanced Technologies, Inc. Method for producing purified hematinic iron-saccharidic complex and product produced
US6825032B2 (en) * 2001-05-14 2004-11-30 Sigma-Aldrich Co. High capacity assay platforms
US7169359B2 (en) * 2002-08-26 2007-01-30 Luitpold Pharmaceuticals, Inc. Bioequivalence test for iron-containing formulations
US6911342B2 (en) * 2002-08-26 2005-06-28 Luitpold Pharmaceuticals, Inc. Bioequivalence test for iron-containing formulations
DE10249552A1 (en) * 2002-10-23 2004-05-13 Vifor (International) Ag Water-soluble iron-carbohydrate complexes, their preparation and medicaments containing them
US7390472B1 (en) * 2002-10-29 2008-06-24 Nei Corp. Method of making nanostructured lithium iron phosphate—based powders with an olivine type structure
US20040161852A1 (en) * 2003-02-14 2004-08-19 Anderson Christopher G. Method of assaying an Fe-Sugar complex
US20060116349A1 (en) * 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
US7964568B2 (en) * 2003-05-30 2011-06-21 Chromaceutical Advanced Technologies, Inc. Synthesis of high molecular weight iron-saccharidic complexes
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
AU2005271897B2 (en) 2004-07-09 2008-06-19 Robert Sabin Compositions and methods of use for treatment of mammalian diseases
AU2007205167B2 (en) * 2006-01-06 2013-06-13 Vifor (International) Ag Methods and compositions for administration of iron
AU2013206429B2 (en) * 2006-01-06 2016-04-28 Vifor (International) Ag Methods and compositions for administration of iron
AU2016205002C1 (en) * 2006-01-06 2020-09-24 Vifor (International) Ag Methods and compositions for administration of iron
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
US20080132465A1 (en) * 2006-12-05 2008-06-05 Vincent Windisch Apparatus and method for isolating iron components from serum
TWI440457B (en) * 2006-12-12 2014-06-11 Ajinomoto Kk Use of citric acid and/or a citrate salt containing composition
TWI468167B (en) 2007-11-16 2015-01-11 威佛（國際）股份有限公司 Pharmaceutical compositions
SI2411053T1 (en) 2009-03-25 2017-04-26 Pharmacosmos Holding A/S A stable iron oligosaccharide compound
US8058076B2 (en) * 2009-03-31 2011-11-15 Astron Research Limited In-vitro method for testing bioequivalence of iron-sucrose formulation
PT104879B (en) * 2009-12-10 2012-10-17 Univ Do Minho DEXTRINO HYDROGEL FOR BIOMEDICAL APPLICATIONS
CN103044571A (en) * 2011-10-13 2013-04-17 天津中敖生物科技有限公司 Iron dextran bulk drug and preparation method thereof
AU2013201308B2 (en) 2011-10-13 2015-01-29 Alebund Pharmaceuticals (Hong Kong) Limited Iron-fiber composition, preparation and uses thereof
JP6417339B2 (en) * 2013-03-08 2018-11-07 ヴィダシム・インコーポレーテッド Metal ion-functional fiber component complex composition, its preparation and use
US9370202B2 (en) * 2013-03-15 2016-06-21 LG Bionano, LLC Encapsulated metal ion nanoclusters
WO2018198135A1 (en) * 2017-04-26 2018-11-01 Mylan Laboratories Ltd. Improved process for the preparation of iron complex
CN111918560A (en) * 2017-12-07 2020-11-10 联邦科学技术研究组织 Reduced sugar products and methods for their production
EP3930686B1 (en) 2019-02-28 2023-05-31 Renibus Therapeutics, Inc. Novel iron compositions and methods of making and using the same
CN113567370A (en) * 2021-07-23 2021-10-29 广西南宁市桃源兽药厂 Method for detecting content of sugar anhydride in iron dextran injection
CN116712455B (en) * 2023-06-30 2024-04-05 重庆汉佩生物科技有限公司 Composition of florfenicol and iron glucoheptonate

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24642E (en) * 1959-04-28 Therapeutic preparations of iron
US2820740A (en) * 1953-02-27 1958-01-21 Benger Lab Ltd Therapeutic preparations of iron
US2885393A (en) * 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3697502A (en) * 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
US3686397A (en) * 1970-05-18 1972-08-22 Mueller Arthur Parenteral iron preparations
US3908004A (en) * 1970-05-20 1975-09-23 C L Basingstoke Limited Process for making injectable iron compositions for treating iron-deficiency anemia
JPS5913521B2 (en) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ Method for producing magnetic iron oxide/dextran complex
US4180567A (en) * 1977-09-02 1979-12-25 Pharmachem Corporation Iron preparations and methods of making and administering the same
DE3026868C2 (en) * 1980-07-16 1986-03-13 Laboratorien Hausmann AG, St. Gallen Process for the preparation of iron (III) hydroxide-dextran complexes and pharmaceutical sterile aqueous solution containing them
US4454773A (en) * 1981-11-06 1984-06-19 Texaco Inc. Time interval automatic well multi-phase fluid sampler
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
JPS58199018A (en) * 1982-05-18 1983-11-19 Nippon Denso Co Ltd Purifying device equipped with electrically heating means for fine particle contained in waste gas
US4659697A (en) * 1983-05-20 1987-04-21 Kentaro Tanaka Antianaemic composition and a process for producing the same
US4788281A (en) * 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
DE3422249A1 (en) * 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln WATER-SOLUBLE IRON DEXTRANE AND METHOD FOR THE PRODUCTION THEREOF
US5102652A (en) * 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5248492A (en) * 1986-07-03 1993-09-28 Advanced Magnetics, Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5336506A (en) * 1986-07-03 1994-08-09 Advanced Magnetics Inc. Targeting of therapeutic agents using polysaccharides
US5118513A (en) * 1987-07-02 1992-06-02 The Procter & Gamble Company Method for enhancing bioavailability of iron-calcium mineral supplements
US5354350A (en) * 1993-12-14 1994-10-11 The Vigoro Corporation Citrate soluble slow release iron humate

Also Published As

Publication number Publication date
EP0855913B1 (en) 2002-06-12
EP0855913A1 (en) 1998-08-05
PT855913E (en) 2002-11-29
ES2179207T3 (en) 2003-01-16
EP0855913A4 (en) 1999-01-20
AU6964796A (en) 1997-04-17
US5624668A (en) 1997-04-29
ATE218875T1 (en) 2002-06-15
DK0855913T3 (en) 2002-10-07
WO1997011711A1 (en) 1997-04-03
JP3471363B2 (en) 2003-12-02
CA2184551A1 (en) 1997-03-30
CA2184551C (en) 2001-11-27
JPH11512706A (en) 1999-11-02
DE69621813D1 (en) 2002-07-18
AU702691B2 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
DE69621813D1 (en) IRON-DEXTRAN FORMULATIONS
IL133890A0 (en) Trifluoroacetyl copolymer - 1
TW368504B (en) Modified arginine deiminase
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
MX9603560A (en) Storage-stable prostaglandin compositions.
MX9804588A (en) Use of halogen bleach-comprising compositions for improved mildness to the skin.
DE69633178D1 (en) Iron compounds, compositions, methods of preparation and uses thereof
TW349000B (en) Fungicidal two-component composition based on R-metalaxyl and usage thereof
TR199701335T1 (en) Diatomaceous earth pest composition
EA199700032A1 (en) DISINFECTING COMPOSITION "VELTOLEN"
DE69614552T2 (en) MODIFIED ALPHA-D-GLCP- (1,2) -ALPHA-D-Glcp- (1,3) -ALPHA-D-Glcp ANALOGS
NO20021429D0 (en) 1,4-dioxacycloalkan-2-one and 1,4-dioxacycloalken-2-one
FI973499A (en) Antitumörbensotiopyranoindazoler
ATE328864T1 (en) ALANINE 2,6-DIALKOXYPHENYL ESTER DERIVATIVES AS HYPNOTICS
FR2729529B1 (en) PLUG-IN INSTALLATION OF ELONGATED PIECES
UA30250A (en) Anti-oxidant remedy
GR1001393B (en) ImidazoÄ2,1-bÜÄ3Übenzazepine derivatives, compositions and method of use.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: VIFOR (INTERNATIONAL) AG, ST. GALLEN, CH

8328 Change in the person/name/address of the agent

Representative=s name: GILLE HRABAL STRUCK NEIDLEIN PROP ROOS, 40593 DüSS